Aprea Therapeutics, Inc. (APRE) is a clinical-stage precision oncology company headquartered in Doylestown, Pennsylvania. It is a stock, not an exchange-traded fund, and it has meaningful — though divergent — analyst coverage.
A review of five current, individually attributable price targets produced a range of $1.20 to $6.00 and an arithmetic mean of roughly $3.84, rounded to a central target of $3.85. The targets reviewed were: H.C. Wainwright (Joseph Pantginis) at $1.20 (Aug. 13, 2026); Ladenburg Thalmann (Kevin DeGeeter) at $2.00, an initiation (Oct. 14, 2026); Oppenheimer (Jay Olson) at $5.00 (Aug. 13, 2026); Maxim Group (Jason McCarthy) at $5.00 (Aug. 14, 2026); and Wedbush (Robert Driscoll) at $6.00 (May 14, 2026).
Every one of these firms rates APRE a Buy or Outperform, so the disagreement is not about direction but magnitude. The cautious end of the range ($1.20) reflects H.C. Wainwright's sharp cut from $4.00 earlier in 2026, while Wedbush has trimmed its target gradually from $11.00 down to $6.00. This widening spread is typical of pre-revenue biotechs whose value hinges on trial readouts rather than earnings.
With shares trading near $0.48 and a 52-week range of roughly $0.41 to $1.49, reaching $3.85 would require an advance of approximately 700%. By any measure, that is a very large move, and it would imply a full re-rating of a company with a market capitalization of only about $6 million.
The plausible path runs through clinical, not financial, milestones. Aprea's lead program, APR-1051, is an oral WEE1 kinase inhibitor in the Phase 1 ACESOT-1051 dose-escalation study. Early data have shown partial responses and stable disease across multiple tumor types with manageable tolerability, and the company is expanding into uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. Each favorable readout has the potential to compress the discount at which the stock trades relative to the analyst range.
APRE has been in a prolonged downtrend, touching an all-time low near $0.41 in late October 2026 and trading far below its 52-week high of $1.49. That $0.41 area now functions as the key support level to defend, while $1.49 represents a distant but significant resistance level. Reaching $3.85 would require not only breaking above $1.49 but sustaining a re-rating well beyond any level seen in the trailing year.
Analyst price targets for biotech names generally reflect a roughly 12-month research horizon, though firms do not always state this explicitly and individual assumptions differ. The most important upcoming items are the next quarterly results (around mid-November 2026), the Q4 2026 update from the ACESOT-1051 Phase 1 trial, and any analyst target revisions that follow. Investors should also watch enrollment progress in the ovarian and uterine cancer expansion cohorts and any further financing announcements.
For traders who prefer a data-driven overlay to fundamental research, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone. If you are looking for a systematic way to complement your own research, exploring the AI Daily Buy/Sell Signals may be a useful next step.
Can APRE reach $3.85? The question frames a very large gap: shares near $0.48 would need to appreciate roughly 700% to reach the average of the five analyst targets reviewed. That mean conceals extraordinary disagreement — from $1.20 at the low end to $6.00 at the high end — because Aprea's value hinges on clinical data for APR-1051 rather than established revenue. Supportive factors include early signs of anti-tumor activity, a funded runway into 2028, and fresh institutional capital, while the principal obstacles are the absence of an approved product, persistent losses, and the inherent binary risk of early-stage oncology trials. The central target should be read as a directional expression of analyst optimism, not a forecast. What matters next is whether the Q4 2026 clinical update substantiates the early activity, and whether the financing remains sufficient to reach meaningful data milestones.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that APRE and ATOS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and ATOS's prices will move in lockstep.
| Ticker / NAME | Correlation To APRE | 1D Price Change % | ||
|---|---|---|---|---|
| APRE | 100% | -11.06% | ||
| ATOS - APRE | 32% Poorly correlated | +0.47% | ||
| WVE - APRE | 28% Poorly correlated | -2.01% | ||
| NTLA - APRE | 28% Poorly correlated | -7.76% | ||
| MBRX - APRE | 27% Poorly correlated | -6.93% | ||
| STTK - APRE | 27% Poorly correlated | -2.81% | ||
More | ||||